|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
06160 BEONE MEDICINES
Nominal 
204.000 +4.500 (+2.256%) | 2026/06 - Interim USD(K$) | %Chg (Compare to Interim) | 2025/12 USD(K$) | 2024/12 USD(K$) | 2023/12 USD(K$) | 2022/12 USD(K$) | |
| Turnover | 3,218,509 | 32.309% | 5,343,033 | 3,810,241 | 2,458,779 | 1,415,921 |
| Cost of Sales | (341,745) | 3.682% | (668,540) | (594,089) | (379,920) | (286,475) |
| Gross Profit | 2,876,764 | 36.795% | 4,674,493 | 3,216,152 | 2,078,859 | 1,129,446 |
| 2026/06 - Interim USD(K$) | %Chg (Compare to Interim) | 2025/12 USD(K$) | 2024/12 USD(K$) | 2023/12 USD(K$) | 2022/12 USD(K$) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | 13,787 | 13.782% | (42,553) | (12,638) | 307,891 | (223,852) | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 571,674 | 374.619% | 416,854 | (533,001) | (825,836) | (1,961,037) | |
| Taxation | (107,310) | 331.675% | (129,921) | (111,785) | (55,872) | (42,778) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 464,364 | 385.787% | 286,933 | (644,786) | (881,708) | (2,003,815) | |
| 2026/06 - Interim USD(K$) | %Chg (Compare to Interim) | 2025/12 USD(K$) | 2024/12 USD(K$) | 2023/12 USD(K$) | 2022/12 USD(K$) | |
| Net Finance Costs / (Income) | 17,062 | -- | (12,271) | (47,836) | (152,382) | (126,714) |
| Depreciation & Amortisation | 81,659 | 19.353% | 141,686 | 171,762 | 87,675 | 66,278 |
| Directors' Emoluments | -- | -- | 29,024 | 27,473 | 25,515 | 24,838 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 32.000 | 357.143% | 20.000 | -47.000 | -65.000 | -149.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 0.795 | (0.103) | (0.853) | (1.116) |
| NBV per share ($) | 3.627 | -- | 2.831 | 2.406 | 2.611 | 3.243 |
| Remarks: | Real time quote last updated: 07/08/2026 11:06 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K$) | USD 464,364 |
| %Change | 385.787% |
| EPS / (LPS) | USD 0.320 |
| NBV Per Share ($) | USD 3.627 |